CPMV (Mosaic ImmunoEngineering) Debt-to-Asset : 567.33 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Mosaic ImmunoEngineering Debt-to-Asset?

Mosaic ImmunoEngineering CPMV Debt-to-Asset is 567.33 as of Jun. 2026. The stock has 1 warning sign investors should review.

Mosaic ImmunoEngineering's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.20 Mil. Mosaic ImmunoEngineering's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $1.50 Mil. Mosaic ImmunoEngineering's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $0.00 Mil. Mosaic ImmunoEngineering's debt to asset for the quarter that ended in Jun. 2026 was 567.33.

Mosaic ImmunoEngineering  (OTCPK:CPMV) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Mosaic ImmunoEngineering Debt-to-Asset Related Terms

Mosaic ImmunoEngineering Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Mosaic ImmunoEngineering's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mosaic ImmunoEngineering Debt-to-Asset Chart

Mosaic ImmunoEngineering Annual Data
Trend May16 May17 May18 May19 May20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.73 4.71 7.32 11.22 83.30

Mosaic ImmunoEngineering Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.09 29.95 83.30 168.40 567.33

CPMV vs CYTOF, LYRA, RGBP: Debt-to-Asset Comparison

For the Biotechnology subindustry, Mosaic ImmunoEngineering's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mosaic ImmunoEngineering Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mosaic ImmunoEngineering's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Mosaic ImmunoEngineering's Debt-to-Asset falls into.


Mosaic ImmunoEngineering Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Mosaic ImmunoEngineering's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.2 + 1.466) / 0.02
=83.30

Mosaic ImmunoEngineering's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.2 + 1.502) / 0.003
=567.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 567.33 mean?
Mosaic ImmunoEngineering (CPMV) has a Debt-to-Asset of 567.33 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Mosaic ImmunoEngineering and its competitors.
Is Mosaic ImmunoEngineering's Debt-to-Asset too high?
Mosaic ImmunoEngineering's current Debt-to-Asset is 567.33.
How does Mosaic ImmunoEngineering's Debt-to-Asset compare to CYTOF and LYRA?
Mosaic ImmunoEngineering's Debt-to-Asset of 567.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Mosaic ImmunoEngineering and its competitors. Mosaic ImmunoEngineering's current Debt-to-Asset is 567.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mosaic ImmunoEngineering stock overvalued right now?
Mosaic ImmunoEngineering (CPMV) has a current Debt-to-Asset of 567.33. The current Debt-to-Asset is 567.33. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Mosaic ImmunoEngineering (CPMV), the current Debt-to-Asset is 567.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mosaic ImmunoEngineering Business Description

Address 9114 Adams Avenue, Suite 202, Huntington Beach, CA, USA, 92646
Mosaic ImmunoEngineering Inc is a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases. It has a single operating segment for the purposes of assessing performance and making operating decisions. The company is pursuing new product candidates and platforms to build a product pipeline based on its deep understanding of immunotherapies.